Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eurasian Medtech System Still 'Officially Targeting' 2021 Deadline

Executive Summary

The mood among various EAEU member states is that the deadline for system adoption should be extended beyond the end of 2021. So far, the authorities have not budged, though progress on system infrastructure continues to be made, according to local regulatory expert Alexey Stepanov.

You may also be interested in...

Countdown To 2022 EUEA System As Russia Increases Post-Market Medtech Controls

There are just 4.5 months left until the new harmonized Eurasian Economic Union medtech system becomes mandatory, signifying major changes in regional market access. EAEU member Russia is meanwhile strengthening its post-market medtech controls.

Russia And Kazakhstan Press On With Medtech Regulatory Work In 2019

Russia and Kazakhstan, two prominent members of the Eurasian Economic Union, are continuing to build national medtech regulatory infrastructures, in the shadow of the forthcoming harmonized EAEU system, of which a postponement beyond 2021 has not been ruled out.

Localism & Local Languages Make For Better Medtech Business In Russia And EAEU

The probability of a postponed entry-in-force of the single Eurasian Economic Union system of medtech regulation has increased over the course of this year, according to speakers at the 2018 Informa KNect 365 Medtech Summit. But the drive for stronger local medtech industries continues, leaving foreign manufacturers with market-access problems to address.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts